Gynecologic cancers

Cancer

Volumn 83, Issue 8 SUPPL., 1998, Pages 1751-1756

  Press, Michael F ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cervical cancer; Endometrial cancer; Gynecologic oncology; Minorities; Molecular genetics; Oncogenes; Ovarian cancer; Tumor suppressor genes

Indexed keywords

CONFERENCE PAPER; ENDOMETRIUM CARCINOMA; MINORITY GROUP; MOLECULAR GENETICS; OVARY CARCINOMA; PAPANICOLAOU TEST; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

EID: 0032531746     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19981015)83:8+<1751::aid-cncr17>3.0.co;2-n     Document Type: Conference Paper

References (34)

1. Parker S, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Haynes M. Geriatric gynecologic care of minorities. Clin Obstet Gynecol 1996;39:946-58.
3. Hulka B. Epidemiologic analysis of breast and gynecologic cancers. Progr Clin Biol Res 1997;396:17-29.
4. Park D, Wilczynski S, Paquette R, Miller C, Koeffler H. P53 mutations in HPV-negative cervical carcinoma. Oncogene 1994;9:205-10.
5. Ikenberg H, Matthay K, Schmitt B, Bauknecht T, et al. p53 mutation and mdm2 amplification are rare even in human papillomavirus-negative cervical carcinomas. Cancer 1995; 76:57-66.
6. Mitra A, Murty V, Pratap M, Sodhani P, Chaganti R. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994;54: 637-9.
7. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T. Prognostic significance of the overexpression of c-erb B-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994;73:148-53.
8. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513-20.
9. Kristensen G, Holm R, Abeler V, Trope C. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erb B-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996; 78:433-4.
10. Wu H. The expression of c-myc protein in uterine cervical cancer: a possible prognostic indicator. Acta Obstet Gynaecol Jan 1996;48:515-21.
11. Lee J, Lee S, Yan M, Ahmed M, Mohiuddin M, Lee E. Expression and mutation of H-ras in uterine cervical cancer. Gynecol Oncol 1996;62:49-54.
12. Kurzrock R, Ku S, Talpaz M. Abnormalities in the PRAD1 (cyclinc D1/bcl-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. Cancer 1995;75: 584-90.
13. Kurman R. Blaustein's pathology of the female genital tract. Berlin: Springer-Verlag, 1994.
14. Matthews R, Hutchinson C, Maiman M, Fruchter RG, Gates EJ, Gibbon D, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:206-12.
15. Lester D, Cauchi M. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. Cancer Lett 1990;51:7-10.
16. Duggan B, Felix J, Muderspach L, Tsao J, Shibata D. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res 1994;54:1604-7.
17. Saffari B, Runnebaum I, Hong D, Niu N, Varkey T, Grill H-J, et al. Association of p53 gene mutations and expression in endometrial cancers with shortened overall survival. Cancer Res 1997. In press.
18. Saffari B, Jones L, el-Naggar A, Felix J, George J, Press M. Amplification and overexpression of HER-2/ neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55(23):5693-8.
19. Reinartz J, George E, Lindgren B, Niehans G. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
20. Leiserowitz G, Harris S, Subramaniam M, Keeney G, Podartz K, Spelsberg T. The proto-oncogene c-fms is overexpressed in endometrial cancer. Gynecol Oncol 1993;49:190-6.
21. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
22. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996;74:562-7.
23. Soravia C, Bapat B, Cohen Z. Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects. Schweiz Med Wochenscr 1997;127:682-90.
24. Qazi F, McGuire W. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995;45:88-101.
25. Wingo P, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995;45:8-30.
26. Teneriello M, Park R. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
27. Tortolero-Luna G, Mitchell M. The epidemiology of ovarian cancer. J Cell Biochem 1995;23(Suppl):200-7.
28. Slamon D, Godolphin W, Jones L, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
29. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
30. Wen W-H, Reles A, Runnebaum I, Sullivan-Halley J, Bernstein L, Jones LA, et al. p53 mutations and expression in ovarian cancers: Correlation with overall survival. Int J Gynecol Pathol 1998; In press.
31. Casey G, Lopez M, Ramos J, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
32. Herrod J, Eliopoulos A, Warwick J, Niedobitek G, Young L, Kerr D. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56: 2178-84.
33. Hartmann L, Podratz K, Keeney G, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-9.
34. Klemi P, Pylkkanen L, Kiilholma P, Kuruvinen K, Joensuu H. P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.